---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-06"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-06. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 95 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence/cdx0159-06"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-06

<a id="heading-3.1.4"></a>

## 3.1.4 CDX0159-06

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Objective stated in the primary publication

> “We assessed the efficacy and safety of various dose regimens of barzolvolimab, a mast cell–depleting anti-KIT antibody, in patients with CSU.”
> “Here we report the results of the primary analysis of a large global phase 2 study evaluating the safety and efficacy of barzolvolimab compared to placebo in CSU patients whose disease is inadequately controlled by antihistamines.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.1-2"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.1-3"></a>

#### Dose-finding purpose stated by the company

> “The study was a randomized, double-blind, placebo-controlled, parallel group Phase 2 study that evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab to determine the optimal dosing strategy.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.1-4"></a>

#### Objectives of the Week 52, follow-up, and off-treatment analyses

> “Here we present the long-term (week 52) analysis of this Phase 2 study”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Here we present the efficacy and safety of barzolvolimab during the 24-week follow up period”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “The objective of this analysis was to characterize off-treatment efficacy among patients who achieved well-controlled disease (UAS7 ≤ 6) after 52 weeks of barzolvolimab treatment”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-05-19”
> “Primary Completion (Actual) 2023-09-28”
> “Study Completion (Actual) 2024-12-20”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 56 locations”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.2-3"></a>

#### Screening dates, last Week 12 visit, and regions in the primary publication

> “From May 19, 2022, to June 15, 2023, a total of 350 patients were screened, of whom 208 were randomly assigned.”
> “the last week 12 visit was September 28, 2023.”
> “The trial included sites in the United States, European Union, and South Africa.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.2-4"></a>

#### Sites and countries stated by the company: 9 countries

> “The study was conducted at approximately 75 clinical trial sites across 9 countries.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.2-5"></a>

#### Sites and countries in the 52-week presentation: 10 countries

> “208 patients enrolled at ~75 sites/10 countries”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.2-6"></a>

#### First participant dosed, June 2022

> “HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU).”

Source: [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)

<a id="topic-3.1.4.2-7"></a>

#### Interim data cut for the 52-week analysis

> “Results based on interim data cut: July 31, 2024”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria”
> “Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple”
> “There is a screening period of up to 4 weeks, followed by a 16-week placebo-controlled treatment period (Placebo-Controlled Treatment Phase) where patients will receive either barzolvolimab at a dose level of 75mg, 150mg, or 300mg, or placebo, and then a 36-week treatment period where all patients will receive barzolvolimab.”
> “Patients who receive barzolvolimab 75mg or placebo in the placebo-controlled treatment phase will be re-randomized to receive either barzolvolimab 150mg or 300mg in the active treatment phase.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.3-2"></a>

#### Study periods, randomization ratio, and stratification in the primary publication

> “This phase 2, randomized, double-blind, placebo-controlled, parallel-group study (NCT05368285) in patients with CSU refractory to antihistamines assessed the efficacy and safety of barzolvolimab.”
> “The study included the following periods: a 2- to 4-week screening phase, a placebo-controlled treatment phase from baseline to week 16 (16 weeks), an active treatment phase from week 16 to week 52 (36 weeks), and a follow-up phase from week 52 to week 76 (24 weeks).”
> “Patients were randomly assigned in a 1:1:1:1 ratio to receive a subcutaneous injection of either barzolvolimab or placebo (saline) once every 4 or 8 weeks according to their assigned cohort (75 mg every 4 weeks; 150 mg every 4 weeks; 300 mg every 8 weeks) over 16 weeks.”
> “Randomization was stratified by baseline disease severity (UAS7 ≤ 27 [moderate] vs UAS7 > 27 [severe]) and baseline absolute neutrophil count (<3000 μL vs 3,000 μL).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.3-3"></a>

#### Blinding and unblinded pharmacist

> “After confirmation of treatment assignment, an unblinded pharmacist/authorized delegate prepared and administered the study treatment for each patient.”
> “All patients and study personnel were blinded to the identity of the study drug until the last enrolled patient completed the last study visit.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.3-4"></a>

#### Dose selection based on healthy volunteer modeling

> “Barzolvolimab doses were selected on the basis of safety, pharmacokinetics, pharmacodynamics (serum tryptase), and clinical effect results from completed and ongoing studies of the intravenous and subcutaneous formulations.”
> “Pharmacokinetic/pharmacodynamic modeling and simulation that was based on population parameters in healthy volunteers were used to estimate exposure for the proposed regimens.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.3-5"></a>

#### Re-randomization at Week 16 and off-treatment follow-up

> “At Week 16, the 75 mg Q4W and placebo groups were re-randomized 1:1 to barzolvolimab 150 mg Q4W or 300 mg Q8W for 36 weeks; other patients remained on their original dose”
> “Following the 52-week study period, patients transitioned into a 24-week off-treatment follow-up”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-3.1.4.3-6"></a>

#### Clinic visits and diaries in each period

> “Patients will complete daily, and weekly diaries and will attend 6 in-clinic visits at Weeks 0, 2, 4, 8, 12 and 16”
> “Patients continue to complete daily and weekly diaries and will attend 9 in-clinic visits at Weeks 20, 24, 28, 32, 36, 40, 44, 48 and 52”
> “Patients continue to complete daily and weekly diaries and will attend 6 in-clinic visits at Weeks 56, 60, 64, 68, 72 and 76”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.3-7"></a>

#### Design stated by the company

> “208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment phase.”
> “After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period.”
> “After 52 weeks, patients then entered a follow-up period for an additional 24 weeks.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Males and females, >/= 18 years of age.”
> “Diagnosis of chronic spontaneous urticaria (CSU) >/= 6 months.”
> “Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.”
> “UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to treatment.”
> “Normal blood counts and liver function tests”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.4-2"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant or nursing.”
> “Clearly defined cause for chronic urticaria.”
> “Active, pruritic skin condition in addition to CSU.”
> “Known active HIV, hepatitis B or hepatitis C infection.”
> “Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study).”
> “History of anaphylaxis”
> “Prior treatment with barzolvolimab”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.4-3"></a>

#### Eligibility in the primary publication, including antihistamine dose and hematology criteria

> “Eligible patients were aged ≥18 years and had CSU refractory to up to 4 times the approved doses of H1AH; patients had to be receiving a stable dose of a single H1AH.”
> “Key inclusion criteria were moderate-to-severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥16”
> “Patients met defined hematology and chemistry criteria (hemoglobin, white blood cell count, absolute neutrophil count, and platelets at or above the lower limit of normal and ≤1.5× the upper limit of normal; aspartate aminotransferase/alanine aminotransferase ≤2× the upper limit of normal and total bilirubin at or below the upper limit of normal at screening visits)”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.4-4"></a>

#### Biologic washout and prior omalizumab in the primary publication

> “Additional key exclusion criteria were receipt of biologic therapy (eg, omalizumab, dupilumab, ligelizumab, or other investigational monoclonal antibodies) within the 3 months before screening visit 1 or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half-lives”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.4-5"></a>

#### Population described in the congress presentations, including prior biologics

> “Patients with moderate to severe CSU who remain symptomatic despite treatment with up to 4X labeled dose of antihistamines and includes patients with prior biologics”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “The overall clinical trial included 207 patients with moderate to severe antihistamine-refractory CSU (UAS7 of ≥16 and a weekly Itch Severity Score [ISS7] of ≥8 for ≥6 months)”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Arms in the ClinicalTrials.gov record

| Arm | Description |
| --- | --- |
| Barzolvolimab 75 mg then 150 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Barzolvolimab 75 mg then 300 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
| Barzolvolimab 150 mg | “barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks” |

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.5-2"></a>

#### Dosing schedule with placebo injections in the every-8-weeks group

> “All patients received treatment on day 1 (baseline) and thereafter every 4 weeks; those randomized to every 8 weeks received placebo injections at the intervening dosing visits.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.5-3"></a>

#### Rescue antihistamine and oral corticosteroids

> “Rescue treatment for patients whose H1AH was at 1 to 3 times the approved dose was additional H1AH, either the same as or different from the background H1AH, not to exceed 4 times the approved dose.”
> “If acute symptoms were still uncontrolled, then a single dose or a short (3 day) course of oral corticosteroids at doses up to prednisone 40 mg (or equivalent) followed by quick tapering was allowed.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.5-4"></a>

#### Last dose at Week 48

> “Last dose of barzolvolimab was at W48”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

> “Seven months after the last dose of barzolvolimab (at Week 48), 41% of patients demonstrated a UAS7=0 (complete response) at Week 76”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Weekly Urticaria Activity Score as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoint and UAS7 definition in the ClinicalTrials.gov record

> “Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)”
> “UAS7 is the sum of the itch severity score measured over 7 days (ISS7) and the hives severity score measured over 7 days (HSS7). The possible range of UAS7 is 0 - 42.”
> “Itch severity score (ISS) is on a scale of 0 - 3.”
> “Hives severity score (HSS) is on a scale of 0 - 3.”
> “From baseline to Day 85 (Week 12)”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.6.1-2"></a>

##### Secondary endpoints in the ClinicalTrials.gov record: ISS7, HSS7, and AAS7

> “Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)”
> “Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)”
> “Mean change from baseline to Week 12 of AAS7 (Angioedema Activity Score)”
> “AAS captures the presences of swelling over the last 24 hours and rates the severity with 5 questions. The possible range of the weekly score is 0 - 105.”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.6.1-3"></a>

##### Complete response as the treatment goal, and UAS7 disease activity categories

> “The goal of CSU therapy is to obtain complete disease response.”
> “Patients with CSU who do not experience complete response to treatment continue to have significant impact of the disease on their quality of life.”
> “(disease activity categories: 0, symptom-free; 1-6, well controlled; 7-15, mild; 16-27, moderate; and 28-42, severe”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

> “Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment and achieving complete response is directly correlated to the greatest improvements in quality of life for patients.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.6.1-4"></a>

##### Secondary and exploratory endpoints in the primary publication, including CSU-free status

> “Secondary and exploratory end points included the mean change and mean percentage change from baseline to week 12 in ISS7, hives severity score over 7 days (HSS7), and Angioedema Activity Score over 7 days (AAS7); the proportion of patients obtaining UAS7 ≤ 6 (well controlled) and UAS7 = 0 (complete response) by week; the proportion of patients obtaining CSU-free status (defined as concurrent ISS7 = 0, HSS7 = 0, and AAS7 = 0) by week; and tryptase serum levels change from baseline to week 12.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.6.1-5"></a>

##### UAS7 health states used for the Week 52 to Week 76 follow-up

> “UAS7 score-based health states were used to describe CSU disease activity throughout the 24-week follow-up period (W52 – W76)”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.6.1-6"></a>

##### Angioedema Activity Score over 7 days: range and dimensions

> “AAS measures 5 dimensions of angioedema (duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity) for the past 24 hours. AAS7 comprises the sum of all AAS dimensions over a 7-day period with scores ranging from 0 to 105, with higher scores indicating more severe symptoms”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.6.1-7"></a>

##### AAS7 improvement of more than 8 points as the clinically meaningful threshold

> “Patients on barzolvolimab experienced a > 8 point improvement in AAS7 (considered a clinically meaningful result) across all doses compared to placebo (p<0.05).”

Source: [Celldex phase 2 CSU angioedema release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-data-demonstrating-profound)

<a id="topic-3.1.4.6.1-8"></a>

##### Urticaria Control Test and Dermatology Life Quality Index: ranges and thresholds

> “Urticaria Control Test (UCT) consists of four questions (on a scale of 0-4; total 0-16) used to assesses symptoms, quality of life, treatment effectiveness and overall disease control in patients with chronic urticaria (spontaneous and inducible). UCT≥12 is well controlled and UCT=16 is complete control.”
> “Dermatology Life Quality Index (DLQI) consists of ten questions (on a scale of 0–3, total 0–30) used to measure the impact of skin disease on patient quality of life related to symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. DLQI 0–1 indicates no effect on a patient’s life.”

Source: [Celldex AAAAI 2026 data release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-additional-positive-data-phase-2-chronic)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Sample size and power in the primary publication

> “A sample size of 168 with 42 patients per group provided 80% power, based on a 2-sided type I error of 0.05, to detect a mean difference in UAS7 from baseline to week 12 between barzolvolimab treatment and placebo of at least 9 points, using a common standard deviation of 14 points and a dropout rate not greater than 15%.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.1-2"></a>

##### Planned enrollment stated at the first dose, June 2022

> “Approximately 168 patients will be randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment phase.”

Source: [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)

<a id="topic-3.1.4.7.1-3"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 208”

Source: [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)

<a id="topic-3.1.4.7.1-4"></a>

##### Participants screened, randomized, treated, and completing Week 12

> “From May 19, 2022, to June 15, 2023, a total of 350 patients were screened, of whom 208 were randomly assigned.”
> “There were 207 patients included in each of the mITT and safety populations.”
> “Overall, 189 patients (91.3%) completed 12 weeks of treatment (Fig 1)”
> “One patient was randomized but not treated.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.1-5"></a>

##### Participants per randomized group in the primary publication

> “randomized 1:1:1:1 to receive barzolvolimab 75 mg every 4 weeks (n = 53); 150 mg every 4 weeks (n = 52); 300 mg every 8 weeks (n = 51); or placebo (n = 51).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.1-6"></a>

##### Participants treated and entering the 24-week follow-up period

> “Here we present the efficacy and safety of barzolvolimab during the 24-week follow up period”
> “208 patients enrolled and 207 patients treated”
> “189 patients entered the follow-up period”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-3.1.4.7.1-7"></a>

##### Participants in the post hoc off-treatment analysis

> “We performed a post hoc analysis of efficacy in patients during the 24-week follow-up period who randomized to barzolvolimab 150 mg Q4W or 300 mg Q8W for 52 weeks (Arm 2 & 3), completed the full treatment period (52 weeks), achieved at least well-controlled disease (UAS7 ≤ 6) at Week 52 (n = 55) and had a reported UAS7 at Week 76 (n = 48)”
> “55/78 (71%) had UAS7 ≤ 6 (well controlled disease) at W52”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.7.1-8"></a>

##### Participants in the angioedema subgroup

> “A total of 149 (72%) patients had angioedema at baseline (AAS7>0)”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.7.1-9"></a>

##### Participants in the pigmentation analysis

> “204 patients received ≥1 dose of barzolvolimab (any dose) and were included in this analysis”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-3.1.4.7.1-10"></a>

##### Participants in the baseline IgE subgroup analysis

> “Analysis was conducted in patients with observable data Weeks 12 and 52. Analysis included patients who received 150 mg or 300 mg of barzolvolimab for 52 weeks. Placebo comparison was done for the week 12 analysis.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Modified intent-to-treat and safety populations

> “The primary analysis was conducted when all patients completed week 12 of treatment.”
> “The modified intent-to-treat (mITT) population was all randomized patients who received at least one dose of study treatment and was analyzed according to the treatment group to which they were randomized.”
> “The safety population was all patients who received at least one dose of study treatment.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.2-2"></a>

##### Handling of missing daily diary scores

> “If a patient had at least 4 nonmissing daily UAS7 scores within the 7 days, the UAS7 score was calculated as the sum of the available diary UAS7 scores in that week, divided by the number of days that had a nonmissing diary UAS7 score, and multiplied by 7.”
> “If there were fewer than 4 nonmissing daily UAS7 scores, then the UAS7 score was considered to be missing.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.2-3"></a>

##### Week 12 primary analysis: analysis of covariance with multiple imputation and Benjamini-Hochberg adjustment

> “The primary comparison was the difference in means between the treatment groups versus placebo at week 12 using an analysis of covariance model with multiple imputation and was assessed by associated least squares (LS) mean differences, standard errors (SEs) and 95% confidence intervals (CIs) for comparing each treatment group vs placebo, and adjusted P values using the Benjamini-Hochberg procedure.”
> “Data for UAS7 well-controlled disease, complete response, and CSU-free status were analyzed in the mITT population by Cochran-Mantel-Haenszel tests for comparison between each active dosing regimen versus placebo.”
> “P values are nominal; only the primary end point P values were adjusted for multiplicity.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.7.2-4"></a>

##### Congress presentations: modified intent to treat and as-observed analyses

> “Modified intent to treat; observed data.”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “Modified intent to treat; observed data in subset of patients with positive AAS7 scores at baseline.”

Source: [Metz et al. (2025c)](https://celldex.com/wp-content/uploads/2025/06/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf)

> “Analyses are as-observed.”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.7.2-5"></a>

##### Pooled dose groups in the safety tables of the congress presentation

> “1 All dose levels (75mgQ4W, 150mgQ4W, 300mgQ8W) combined; 2 All dose levels combined; patients randomized to 75mgQ4W were re-randomized to 150mgQ4W or 300mgQ8W at week 16; 3 Patients received 36 weeks of barzolvolimab 150mgQ4W or 300mgQ8W after 16 weeks of placebo; data are shown for 36 week barzolvolimab experience”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.7.2-6"></a>

##### Post hoc subgroup analyses by baseline IgE and baseline serum tryptase

> “Statistical analyses to determine significance between groups was conducted using one-way ANOVA with Tukey’s Multiple Comparisons Test, Welch's t-test, or z-test for two population proportions, as appropriate.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

> “Exploratory, post hoc efficacy analyses from the Phase 2, double-blind, placebo-controlled study (NCT05368285) assessed the association of baseline serum tryptase with baseline disease severity and response to barzolvolimab at Week 12 and Week 52 in patients with H1-antihistamine-refractory CSU”
> “Receiver operating characteristic (ROC) analyses evaluated baseline serum tryptase as a predictor of treatment response”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Disposition through Week 12

> “There were 207 patients included in each of the mITT and safety populations.”
> “Overall, 189 patients (91.3%) completed 12 weeks of treatment (Fig 1)”
> “One patient was randomized but not treated.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.1-2"></a>

##### Treatment discontinuations through Week 52 by randomized group

| Reason | 75 mg every 4 weeks, then 150 or 300 mg | 150 mg every 4 weeks | 300 mg every 8 weeks | Placebo, then 150 or 300 mg |
| --- | --- | --- | --- | --- |
| Group size | “(n=53)” | “(n=52)” | “(n=52)” | “(n=51)” |
| Discontinued treatment, n (%) | “13 (25%)” | “13 (25%)” | “13 (25%)” | “8 (16%)” |
| Adverse event | “7 (13%)” | “4 (8%)” | “7 (13%)” | “2 (4%)” |
| Patient decision | “1 (2%)” | “3 (6%)” | “1 (2%)” | “3 (6%)” |
| Non-compliance | “2 (4%)” | “1 (2%)” | “1 (2%)” | “2 (4%)” |
| Lack of clinical response | “1 (2%)” | “0” | “2 (4%)” | “1 (2%)” |
| Other | “2 (4%)” | “5 (10%)” | “2 (4%)” | “0” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Patient Disposition Through 52 Weeks”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.1-3"></a>

##### Discontinuations during the 16-week placebo-controlled period and adverse events leading to discontinuation

> “Three patients discontinued placebo during the 16 week placebo-controlled period due to patient decision (2), non compliance (1)”
> “Adverse event discontinuations in more than one patient: hair color changes (6), urticaria (5), macrocytic anemia (2)”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.1-4"></a>

##### Participants treated and entering the follow-up period

> “208 patients enrolled and 207 patients treated”
> “189 patients entered the follow-up period”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Demographics and baseline disease characteristics by randomized group

| Characteristic | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Placebo (n = 51) |
| --- | --- | --- | --- | --- |
| Age (years), median (range) | “42.0 (18-69)” | “44.5 (21-81)” | “49.0 (20-80)” | “43.0 (20-76)” |
| Female sex, no. (%) | “40 (75.5)” | “39 (75.0)” | “41 (80.4)” | “36 (70.6)” |
| Weight (kg), mean (SD) | “77.49 (20.442)” | “80.86 (21.354)” | “85.73 (24.852)” | “83.81 (19.866)” |
| UAS7 score, mean (SD) | “30.30 (8.057)” | “30.75 (7.657)” | “31.33 (6.939)” | “30.09 (8.057)” |
| UAS7, severe disease (UAS7 ≥ 28), no. (%) | “34 (64.2%)” | “36 (69.2%)” | “39 (76.5%)” | “33 (64.7%)” |
| ISS7 score, mean (SD) | “15.44 (4.053)” | “15.70 (4.004)” | “16.42 (3.658)” | “15.61 (3.783)” |
| HSS7 score, mean (SD) | “14.86 (4.588)” | “15.05 (5.045)” | “14.92 (4.387)” | “14.47 (4.842)” |
| UCT score, mean (SD) | “3.67 (2.826)” | “3.67 (2.503)” | “2.96 (2.630)” | “3.38 (2.472)” |
| Angioedema at baseline (AAS7 > 0), no. (%) | “40 (75.5%)” | “35 (67.3%)” | “42 (82.4%)” | “32 (62.7%)” |
| Duration of CSU (years), mean (SD) | “5.44 (5.352)” | “5.47 (6.538)” | “6.28 (6.554)” | “5.27 (6.565)” |
| Previous experience with omalizumab, no. (%) | “11 (20.8)” | “11 (21.2)” | “11 (21.6)” | “8 (15.7)” |
| Baseline IgE (IU/mL), median (IQR) | “81 (27.0-271.0)” | “60 (13.0-135.0)” | “91.5 (35.5-218.0)” | “101.5 (25.0-237.8)” |
| Dermatology Life Quality Index, mean (SD) | “15.88 (7.596)” | “15.65 (7.634)” | “17.37 (7.534)” | “16.98 (6.556)” |
| Baseline tryptase (ng/mL), median (IQR) | “5.25 (3.43-6.80)” | “5.40 (4.30-6.90)” | “4.80 (3.85-6.55)” | “4.40 (3.25-6.55)” |

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.2-2"></a>

##### Baseline imbalances in the 300 mg every 8 weeks group

> “In the 300 mg barzolvolimab group at baseline, there were more patients with higher body weights, more patients with severe CSU (UAS7 ≥ 28), and a higher percentage of patients with angioedema (82%) than the lower-dose groups of barzolvolimab and the placebo group.”
> “Overall, the patient population in this study had severe CSU measured by UAS7 (≥28), Urticaria Control Test score (<6), high rate of angioedema (>60%), and long duration of CSU (>5 years).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.2-3"></a>

##### Prior omalizumab and omalizumab-refractory disease

> “Approximately 20% (n=41) of enrolled patients received prior treatment with omalizumab and more than half of these patients had omalizumab-refractory disease.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.2-4"></a>

##### Baseline AAS7 in participants with angioedema at baseline

> “In patients with angioedema at baseline, mean AAS7 at baseline ranged from 53 to 56 points, indicating that patients presented with severe angioedema symptoms prior to treatment”
> “Patients with angioedema had numerically longer disease duration and worse quality of life (as measured by Dermatology Quality of Life Index [DLQI]) vs patients without angioedema at baseline”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.8.2-5"></a>

##### Baseline UCT and DLQI in the 150 mg and 300 mg groups

> “Baseline mean (SD) UCT scores were 3.7 (2.5) and 3.0 (2.6) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating poorly controlled urticaria.”
> “Baseline mean (SD) DLQI was 15.7 (7.6) and 17.4 (7.5) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating a very large impact of disease on QoL.”

Source: [Maurer et al. (2025a)](https://doi.org/10.1016/j.jaci.2024.12.985)

<a id="topic-3.1.4.8.2-6"></a>

##### Baseline characteristics of participants with well-controlled disease at Week 52

> “Patients With Well Controlled Disease at Week 52”
> “66.7% and 68.9% of patients had severe CSU and angioedema, respectively, at baseline”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Week 12 primary endpoint: UAS7 change from baseline versus placebo

> “There was significant improvement in mean (95% confidence interval) change from baseline to week 12 in UAS7 in barzolvolimab-treated patients compared to patients who received placebo (75 mg every 4 weeks: -6.60 [-10.71, -2.49] P = .0017; 150 mg every 4 weeks: -12.55 [-16.56, -8.55] P < .0001; 300 mg every 8 weeks: -13.41 [-17.47, -9.34] P < .0001).”
> “Barzolvolimab demonstrated a rapid (within 2 weeks) and marked improvement in UAS7 scores through week 12 (Fig 2, B).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-2"></a>

##### Week 12 efficacy endpoints by randomized group

| Endpoint at Week 12 | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Placebo (n = 51) |
| --- | --- | --- | --- | --- |
| UAS7 LS mean change from baseline (SE) | “−17.06 (1.493)” | “−23.02 (1.416)” | “−23.87 (1.479)” | “−10.47 (1.462)” |
| UAS7 treatment difference vs placebo (95% CI) | “−6.60 (−10.71, −2.49)” | “−12.55 (−16.56, −8.55)” | “−13.41 (−17.47, −9.34)” | Not applicable |
| ISS7 LS mean change from baseline (SE) | “−8.62 (0.794)” | “−11.68 (0.766)” | “−11.79 (0.788)” | “−5.47 (0.784)” |
| ISS7 treatment difference vs placebo (95% CI) | “−3.16 (−5.41, −0.91)” | “−6.21 (−8.38, −4.04)” | “−6.32 (−8.50, −4.13)” | Not applicable |
| HSS7 LS mean change from baseline (SE) | “−8.25 (0.747)” | “−11.19 (0.750)” | “−12.19 (0.745)” | “−4.95 (0.772)” |
| HSS7 treatment difference vs placebo (95% CI) | “−3.31 (−5.40, −1.22)” | “−6.24 (−8.33, −4.16)” | “−7.24 (−9.36, −5.12)” | Not applicable |
| AAS7 LS mean change from baseline (SE) | “−24.10 (2.831)” | “−27.99 (2.815)” | “−29.95 (2.843)” | “−12.56 (3.056)” |
| AAS7 treatment difference vs placebo (95% CI) | “−11.55 (−20.04, −3.05)” | “−15.43 (−23.52, −7.34)” | “−17.39 (−25.49, −9.30)” | Not applicable |
| Well-controlled disease (UAS7 ≤ 6) (%) | “41.7” | “59.6” | “62.5” | “12.8” |
| UAS7 ≤ 6 difference in proportions vs placebo (95% CI) | “0.29 (0.12, 0.46)” | “0.47 (0.3, 0.64)” | “0.50 (0.33, 0.66)” | Not applicable |
| Complete control (UAS7 = 0) (%) | “22.9” | “51.1” | “37.5” | “6.4” |
| UAS7 = 0 difference in proportions vs placebo (95% CI) | “0.17 (0.03, 0.3)” | “0.45 (0.29, 0.61)” | “0.31 (0.16, 0.46)” | Not applicable |
| CSU-free status (ISS7 = 0, HSS7 = 0, and AAS7 = 0) (%) | “19.2” | “50.0” | “33.3” | “5.9” |

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-3"></a>

##### Week 12 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) versus placebo

> “UAS7 responses to barzolvolimab were greater for all doses versus placebo: 41.7% of 75 mg every 4 weeks, 59.6% of 150 mg every 4 weeks, and 62.5% of 300 mg every 8 weeks barzolvolimab-treated patients had well-controlled disease (UAS7 ≤ 6) at week 12 compared to 12.8% of patients who received placebo (Fig 2, C, P < .01 for all comparisons with placebo; Table II).”
> “Similarly, 22.9% of 75 mg every 4 weeks, 51.1% of 150 mg every 4 weeks, and 37.5% of 300 mg every 8 weeks barzolvolimab-treated patients experienced complete response (UAS7 = 0) at week 12 compared to 6.4% of patients who received placebo (Fig 2, D, P < .05 for all comparisons with placebo; Table II).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-4"></a>

##### Week 12 UAS7 change by prior omalizumab treatment

> “Patients with prior omalizumab treatment also demonstrated benefits on LS mean change from baseline in UAS7 at week 12 (nominal P = .0322, P = .0236, and P = .005 for the 75 mg every 4 weeks, 150 mg every 4 weeks and 300 mg every 8 weeks barzolvolimab groups, respectively) that were numerically similar to benefits in omalizumab-naïve patients and the overall population; similar trends were observed in patients in the omalizumab-refractory subgroup, although the number of patients in this subgroup was small (Fig 3).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-5"></a>

##### Week 12 angioedema activity (AAS7) in participants with angioedema at baseline

> “Barzolvolimab treatment also resulted in rapid (within 1 week) and durable symptom improvement for patients with angioedema at baseline in AAS7 change from baseline through week 12 compared to patients who received placebo (Fig 4 and Table II; nominal P < .01 for all barzolvolimab doses vs placebo).”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-6"></a>

##### Week 12 AAS7 improvement of more than 8 points and angioedema-free days

| Measure at Week 12 (participants with angioedema at baseline) | 300 mg every 8 weeks | 150 mg every 4 weeks | 75 mg every 4 weeks | Placebo |
| --- | --- | --- | --- | --- |
| Angioedema at baseline, n (%) | “42 (82%)” | “35 (67%)” | “40 (75%)” | “32 (63%)” |
| Baseline AAS7 (mean) | “53.15” | “54.60” | “54.05” | “56.30” |
| >8 point improvement in AAS7 (%) | “85.0” | “87.1” | “82.9” | “57.1” |
| Angioedema free days (mean) | “65.1” | “54.5” | “43.3” | “36.2” |

Source: [Celldex phase 2 CSU angioedema release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-data-demonstrating-profound)

> “AAS7 data were analyzed using ANCOVA model and multiple imputation. Data are presented for patients with angioedema at baseline.”
> “Barzolvolimab increased angioedema free days compared to placebo through 12 weeks. Patients in the 300 mg cohort were angioedema free 77% of the time over the 12 week period.”

Source: [Celldex phase 2 CSU angioedema release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-data-demonstrating-profound)

<a id="topic-3.1.4.8.3-7"></a>

##### Week 12 serum tryptase reduction

> “Reductions in serum tryptase, a correlate of MC load,”
> “were apparent in patients treated with barzolvolimab, but not with placebo, and were numerically greater for the 150 mg every 4 weeks and 300 mg every 8 weeks treatment groups, than for the 75 mg every 4 weeks treatment group.”
> “Serum tryptase at baseline and week 12 in indicated subgroups.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.3-8"></a>

##### Week 52 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) after re-randomization at Week 16

| Group | UAS7 ≤ 6 at Week 12 (%) | UAS7 ≤ 6 at Week 52 (%) | UAS7 = 0 at Week 12 (%) | UAS7 = 0 at Week 52 (%) |
| --- | --- | --- | --- | --- |
| 75 mg every 4 weeks, then 150 or 300 mg | “41.7” | “67.4” | “22.9” | “53.5” |
| 150 mg every 4 weeks | “59.6” | “73.7” | “51.1” | “71.1” |
| 300 mg every 8 weeks | “62.5” | “68.2” | “37.5” | “52.3” |
| Placebo, then 150 or 300 mg | “12.8” | “63.0” | “6.4” | “58.7” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Placebo and 75mg Q4W re-randomized to 150mg Q4W or 300mg Q8W at Week 16”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.3-9"></a>

##### Week 52 response stated by the company and by prior omalizumab experience

> “71% of patients treated with barzolvolimab 150 mg Q4W and 52% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 52. These responses were observed early and sustained through 52 weeks.”
> “At Week 16, patients receiving low dose barzolvolimab (75 mg) or placebo were transitioned to barzolvolimab 150 mg or 300 mg; after crossover, these patients experienced similar clinically meaningful disease response as the rest of the study population.”
> “These robust responses were observed regardless of prior omalizumab experience.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.3-10"></a>

##### Week 52 angioedema activity (AAS7) in participants with angioedema at baseline

> “Barzolvolimab improvement from baseline: 86% reduction for 150 mg Q4W and 82% reduction for 300 mg Q8W at Week 52”
> “Patients who received 150 mg Q4W and 300 mg Q8W were angioedema free 72% and 70% of the time over the 52-week period.”
> “Placebo treated patients had 33% of angioedema free days through Week 12.”
> “Up to 87% of patients reported clinically meaningful improvement (≥8 point) in AAS7 at Week 52”
> “Up to 77% of patients who had angioedema at baseline were angioedema free at Week 52”

Source: [Metz et al. (2025c)](https://celldex.com/wp-content/uploads/2025/06/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf)

<a id="topic-3.1.4.8.3-11"></a>

##### Week 52 and Week 76 AAS7 change and angioedema-free status (AAS7 = 0) across the four groups

> “At week 52, the mean change from baseline was similar across the 4 treatment groups, ranging from -39.82 to -47.75”
> “At 28 weeks after their last dose, the mean change across treatment groups ranged from -31.52 to -43.11”
> “At week 52, between 67% and 77% of patients with angioedema at baseline across the 4 treatment groups reached AAS7=0”
> “At 28 weeks after their last dose, between 52% to 64% of patients across the 4 treatment groups were angioedema-free”

Source: [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)

<a id="topic-3.1.4.8.3-12"></a>

##### Week 12 and Week 52 efficacy by baseline IgE

> “Changes in UAS7 or UCT7 at Weeks 12 and 52”
> “Patients receiving placebo, or barzolvolimab at 150 mg Q4W or 300 mg Q8W were subgrouped according to baseline IgE levels as previously defined”
> “Similarly strong efficacy was observed in patients with normal/high (≥ 40 IU/mL) or low (< 40 IU/mL) IgE levels for both dosing regimens as determined by:”
> “Adjusted p-value was non-significant for all comparisons between normal/high vs IgE low subgroups in indicated analyses.”
> “The rate ratio (95% CI) of achieving a complete response in patients with low compared to normal/high baseline IgE was 1.37 (0.74-2.55) and 1.24 (0.71-2.16) in the 150 mg Q4W and 300 mg Q8W groups, respectively.”

Source: [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)

<a id="topic-3.1.4.8.3-13"></a>

##### Week 12 and Week 52 efficacy by baseline serum tryptase

> “Baseline serum tryptase is not predictive of barzolvolimab response at Week 12 or Week 52”
> “ROC analysis showed no predictive value of baseline serum tryptase for response (AUC ≤0.56)”
> “Baseline serum tryptase was not associated with baseline disease severity nor was predictive of barzolvolimab response”

Source: [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)

<a id="topic-3.1.4.8.3-14"></a>

##### Week 76, 28 weeks after the last dose: UAS7 change, UAS7 = 0, and UAS7 ≤ 6

> “In this Phase 2 trial (n=208) of barzolvolimab in patients with antihistamine-refractory CSU, sustained treatment benefits were observed over 28 weeks after the last dose”
> “UAS7 Mean CFB (SE) at W76”
> “150 mg Q4W was -20.4 (2.5)”
> “300 mg Q8W was -21.1 (1.9)”
> “UAS7=0 (%) at W76”
> “150 mg Q4W was 41%”
> “300 mg Q8W was 35%”
> “UAS7≤6 (%) at W76”
> “150 mg Q4W was 56%”
> “300 mg Q8W was 47%”
> “Modified intent to treat; observed data.”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-3.1.4.8.3-15"></a>

##### Week 76 UAS7 change stated by the company

> “UAS7 mean change from baseline at Week 76 was -20.42 for patients treated with 150 mg Q4W and -21.10 for patients treated with 300 mg Q8W.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.3-16"></a>

##### Week 76 in participants with well-controlled disease (UAS7 ≤ 6) at Week 52

> “In a Phase 2 trial of patients with antihistamine-refractory CSU treated with barzolvolimab (150 mg Q4W or 300 mg Q8W for 1 year), 71% had well controlled disease at the end of the treatment period”
> “Of those with at least well controlled disease, 88% had a complete response (UAS7 = 0)”
> “69% of patients who achieved well controlled disease after 52 weeks of treatment, also achieved well controlled disease at week 76”
> “50% of patients who achieved well controlled disease after 52 weeks of treatment, achieved complete response at week 76”
> “Concentration of barzolvolimab falls below therapeutic levels by week 64”
> “Tryptase recovers towards range of healthy subjects by week 76 indicating normal mast cell numbers”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.8.3-17"></a>

##### Week 76 disease severity at recurrence after treatment completion

> “For patients who did experience recurrence of disease symptoms after treatment completion, their disease was much milder than what it was at baseline.”
> “83% reported no impact of disease on QoL (DLQI 0/1) at Week 76 and 74% of patients with angioedema at baseline were angioedema free (AAS7=0)”

Source: [Celldex AAAAI 2026 data release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-additional-positive-data-phase-2-chronic)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

##### Week 12 Urticaria Control Test (UCT7): treatment differences versus placebo

> “At baseline, mean UCT7 scores ranged from 3.8-5.5, indicating poor disease control.”
> “Treatment with barzolvolimab led to markedly improved disease control, with least squares mean (95% CI) treatment differences in change from baseline UCT7 at 12W of 5.8 (4.2, 7.5) and 4.8 (3.1, 6.5) for 150mg Q4W and 300mg Q8W, respectively (both p<0.0001).”
> “Over 89% of patients achieved a clinically meaningful benefit in UCT7 at 12W.”

Source: [Metz et al. (2025f)](https://www.annallergy.org/article/S1081-1206%2825%2900523-X/fulltext)

<a id="topic-3.1.4.8.4-2"></a>

##### Well-controlled urticaria (UCT7 ≥ 12) at 12 and 52 weeks and 28 weeks after the last dose

> “At least well-controlled urticaria (UCT7≥12) was achieved in 68.1% and 61.7% (12 weeks) and 85.7% and 71.4% (52 weeks) for the 150mg Q4W and 300mg Q8W doses, respectively.”
> “Well-controlled urticaria was still present at 28 weeks following the last dose of barzolvolimab in 59.4% and 53.6% of patients, respectively.”

Source: [Metz et al. (2025f)](https://www.annallergy.org/article/S1081-1206%2825%2900523-X/fulltext)

<a id="topic-3.1.4.8.4-3"></a>

##### Week 12 DLQI 0 or 1 and UCT ≥ 12

> “These data are from the 12 week analysis. 67% and 57% of patients treated with 150 mg Q4W or 300 mg Q8W, respectively, reported improvement of CSU and their quality of life (DLQI score of 0 or 1). The majority of patients (>65%) treated with 150 mg Q4W or 300 mg Q8W achieved well-controlled urticaria (UCT≥12).”

Source: [Celldex phase 2 CSU 52-week results release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-landmark-52-week-results)

<a id="topic-3.1.4.8.4-4"></a>

##### Week 52 UCT and DLQI change from baseline in the 150 mg and 300 mg groups

> “Baseline mean (SD) UCT scores were 3.7 (2.5) and 3.0 (2.6) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating poorly controlled urticaria.”
> “Treatment demonstrated marked improvement in UCT, with mean (SD) change from baseline (CFB) at 52 weeks 10.5 (3.9) and 9.4 (5.0), respectively.”
> “Baseline mean (SD) DLQI was 15.7 (7.6) and 17.4 (7.5) in the 150mg Q4W and 300mg Q8W groups, respectively, indicating a very large impact of disease on QoL.”
> “At 52 weeks, the mean CFB in DLQI was -14.2 (7.3) and -15.0 (8.5), respectively.”

Source: [Maurer et al. (2025a)](https://doi.org/10.1016/j.jaci.2024.12.985)

<a id="topic-3.1.4.8.4-5"></a>

##### Week 52 DLQI 0 or 1, DLQI improvement, and UCT control stated by the company

> “Up to 82% of patients reported that CSU symptoms no longer had an impact on their quality of life at Week 52 and up to 95% of patients reported meaningful improvement in quality of life based on DLQI at Week 52.”
> “Up to 82% of patients reported well-controlled urticaria based on UCT, and approximately half of patients reported complete control at Week 52.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.4-6"></a>

##### Week 76 DLQI 0 or 1

> “DLQI 0 or 1 at W76”
> “150 mg Q4W was 48%”
> “300 mg Q8W was 40%”
> “Modified intent to treat; observed data.”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

<a id="topic-3.1.4.8.4-7"></a>

##### Week 76 DLQI in participants with well-controlled disease (UAS7 ≤ 6) at Week 52

> “The mean (SE) DLQI at W76 for patients with well controlled disease at week 52 was 1.2 (0.75)”
> “20/24 (83%) reported a DLQI 0/1 (no impact of disease on QoL) at week 76”

Source: [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)

<a id="topic-3.1.4.8.4-8"></a>

##### Week 52 and Week 76 DLQI in the post hoc quality of life analysis

> “In the post hoc analysis presented at AAD, the impact of disease on QoL for the subset of patients who received 52 weeks of barzolvolimab therapy (150 mg Q4W or 300 mg Q8W) and completed treatment with at least well controlled disease (UAS7<6) at Week 52 and had DLQI data through Week 76 was explored.”
> “At Week 52, 94% of patients with well controlled disease at Week 52 also had a DLQI of 0/1, indicating their disease had no impact on their QoL .”
> “76% of patients with well controlled disease at Week 52 also reported that the disease had small to no impact (DLQI score ≤ 5) on their QoL at Week 76.”
> “Profound improvements were observed across all 6 domains at both Weeks 52 and 76.”

Source: [Celldex AAD 2026 quality of life release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-positive-data-phase-2-chronic-spontaneous)

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Baseline through Week 12: adverse events, serious adverse events, and discontinuations

> “Safety and tolerability of barzolvolimab were assessed by the proportion of patients reporting treatment-emergent adverse events (TEAEs) and serious AEs, and TEAEs leading to treatment discontinuation from baseline through week 12.”
> “Overall, 88 barzolvolimab-treated patients (56.4%) and 14 patients who received placebo (27.5%) reported a TEAE.”
> “In the 300 mg every 8 weeks group, one barzolvolimab-treated patient (2.0%) experienced a serious AE of external ear canal cholesteatoma that was considered unrelated to treatment and resolved during the study.”
> “A total of 7 barzolvolimab-treated patients (4.5%) experienced a TEAE that led to study treatment discontinuation; this included neutropenia (n = 2), abdominal pain (n = 1), hair color change (n = 3), dizziness (n = 1), urticaria (n = 1), and thrombocytopenia (n = 1).”
> “None of the patients who received placebo had a TEAE that led to study treatment discontinuation. There were no deaths during the study.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

| Event | 75 mg every 4 weeks (n = 53) | 150 mg every 4 weeks (n = 52) | 300 mg every 8 weeks (n = 51) | Pooled barzolvolimab (n = 156) | Placebo (n = 51) |
| --- | --- | --- | --- | --- | --- |
| Patients with ≥1 TEAE | “28 (52.8)” | “29 (55.8)” | “31 (60.8)” | “88 (56.4)” | “14 (27.5)” |
| Patients with serious AE | “0” | “0” | “1 (2.0)” | “1 (0.6)” | “0” |
| Discontinued study treatment due to TEAE | “2 (3.8)” | “1 (1.9)” | “4 (7.8)” | “7 (4.5)” | “0” |
| Hair color changes | “0” | “5 (9.6)” | “9 (17.6)” | “14 (9.0)” | “0” |
| Urticaria/CSU | “8 (15.1)” | “5 (9.6)” | “3 (5.9)” | “16 (10.3)” | “5 (9.8)” |
| Neutropenia (neutropenia and neutrophil count decreased) | “4 (7.6)” | “3 (5.7)” | “5 (9.8)” | “12 (7.7)” | “0” |

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.5-2"></a>

##### Week 12 neutropenia: onset, duration, and infections

> “Similar to other AEs, most events of neutropenia/decreased neutrophil count were of mild to moderate intensity; the onset typically occurred within 1 to 3 months and lasted 3 to 4 weeks while receiving treatment.”
> “Although neutropenia was observed in 7.7% of barzolvolimab-treated patients, it was not associated with infections.”
> “Analysis of hematology laboratory parameters showed a 1.65 × 109/L mean decrease in neutrophils in the barzolvolimab-treated patients between baseline and week 12”
> “There was one patient in the 75 mg barzolvolimab group with two consecutive neutrophil counts in the grade 3 range”
> “and this patient was discontinued, as per the study’s protocol.”

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)

<a id="topic-3.1.4.8.5-3"></a>

##### Week 12 adverse events stated by the company

> “Most adverse events were mild to moderate in severity; through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were urticaria/CSU (10%), hair color changes (9%), and neutropenia/ANC decrease (8%). The rate of infections was similar between barzolvolimab treated patients and placebo with no association between neutropenia and infections.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.5-4"></a>

##### Week 16 placebo-controlled period and Week 52 full treatment period: adverse events

| Patients, n (%) | Barzolvolimab, all doses, Weeks 0 to 16 (N= 156) | Placebo, Weeks 0 to 16 (N= 51) | Barzolvolimab, all doses, Weeks 0 to 52 (N= 156) | Placebo then barzolvolimab, 36 weeks (N=48) |
| --- | --- | --- | --- | --- |
| At least one AE | “103 (66)” | “20 (39)” | “139 (89)” | “32 (67)” |
| Treatment related SAEs | “0” | “0” | “2 (1)” | “0” |
| Hair color changes | “22 (14)” | “0” | “40 (26)” | “8 (17)” |
| Neutropenia / neutrophil count decreased | “14 (9)” | “0” | “26 (17)” | “2 (4)” |
| Urticaria | “15 (10)” | “5 (10)” | “23 (15)” | “3 (6)” |
| Skin hypopigmentation | “2 (1)” | “0” | “21 (13)” | “9 (19)” |
| Nasopharyngitis | “6 (4)” | “3 (6)” | “15 (10)” | “4 (8)” |

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

> “Placebo Controlled Period (16 weeks)”
> “Full Treatment Period (52 weeks)”
> “4 SAEs of worsening urticaria symptoms”
> “Most events were grade 1 (mild), mechanism-related (KIT) and expected to be reversible”
> “Adverse events were not dose dependent”
> “No association between infections and neutropenia/decreased neutrophil counts”

Source: [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)

<a id="topic-3.1.4.8.5-5"></a>

##### Week 52 neutrophil counts and skin hypopigmentation stated by the company

> “Barzolvolimab was well tolerated with a favorable safety profile through 52 weeks of treatment.”
> “Neutrophil counts did not decline further with continued dosing and there was no association between infections and neutropenia. The hypopigmentation was observed with longer term exposure and did not lead to treatment discontinuation.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.5-6"></a>

##### Follow-up period through 76 weeks: neutrophil recovery and reversibility of pigment changes

> “Barzolvolimab was well tolerated with no new safety findings identified during follow up period”
> “Neutropenia/neutrophil count events resolved while on treatment and were not associated with infection”
> “Resolution of hair color changes and skin hypopigmentation observed following discontinuation of treatment”

Source: [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)

> “Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. No new safety signals were identified during the follow-up period. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-3.1.4.8.5-7"></a>

##### Hair color and skin pigmentation changes over 76 weeks: incidence, onset, severity, and resolution

> “The objective of this analysis was to assess the rate and reversibility of pigmentation changes over 76 weeks in patients with CSU treated with barzolvolimab”
> “Hair color changes (hypopigmentation) occurred in 49 (24%) patients; 96% of hair color changes were mild (Grade 1). Mean time to onset was ≈4 months, with 91% of evaluable patients reporting resolution of hair color change by the end of study participation”
> “Skin hypopigmentation occurred in 36 (18%) patients and events were mostly mild (94%; Grade 1); mean onset was ≈9 months, with 68% of evaluable patients reporting resolution by data cutoff”
> “Skin hyperpigmentation occurred in 6 (3%) patients, all of whom reported the events as mild (Grade 1); mean time to onset was ≈5 months, with 67% of evaluable patients reporting resolution by data cutoff (photographs not available)”
> “Discontinuation due to pigmentation changes was low (hair color changes: 3%, n=6; skin hypopigmentation, n=0; skin hyperpigmentation: <0.5%, n=1 )”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="topic-3.1.4.8.5-8"></a>

##### Limitations of the pigmentation photography stated by the authors

> “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes”
> “Images were obtained from a subset of patients and may not be representative of all events observed in the trial.”

Source: [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

- Sample size: the study was sized at 168 participants (42 per group) for 80% power to detect a UAS7 difference of at least 9 points at week 12. Of 208 participants randomized, 207 were in the mITT and safety populations. Approximately 20% (n=41) had prior omalizumab, and the authors state of the omalizumab-refractory subgroup that “the number of patients in this subgroup was small”.
- Duration of placebo control: the placebo-controlled treatment phase ran from baseline to week 16. At Week 16 the placebo and 75 mg groups were re-randomized 1:1 to 150 mg Q4W or 300 mg Q8W for 36 weeks, so every group received barzolvolimab from Week 16 to Week 52.
- Peer-reviewed scope: the primary publication reports the primary analysis, conducted when all participants completed week 12. Week 52 results are from a congress presentation based on an interim data cut of July 31, 2024, and Week 76 results are from congress presentations and the Form 10-Q.
- Multiplicity: the publication states “P values are nominal; only the primary end point P values were adjusted for multiplicity.”
- Missing data: the week 12 primary analysis used analysis of covariance with multiple imputation, while the Week 76 and angioedema congress analyses are labeled modified intent to treat with observed data or as-observed. Overall, 189 participants (91.3%) completed 12 weeks of treatment. Through 52 weeks, 13 (25%) participants in each of the three barzolvolimab groups and 8 (16%) in the placebo-then-barzolvolimab group discontinued treatment, including 7 (13%), 4 (8%), 7 (13%), and 2 (4%) for adverse events.
- Off-treatment and post hoc analyses: the last dose was at Week 48, followed by a 24-week off-treatment follow-up from Week 52 to Week 76. The off-treatment efficacy analysis was post hoc and limited to participants randomized to 150 mg Q4W or 300 mg Q8W who completed 52 weeks with UAS7 ≤ 6 at Week 52 (n = 55), of whom 48 had a reported UAS7 at Week 76. The baseline serum tryptase analyses were exploratory and post hoc.
- Baseline imbalance: the 300 mg group had more participants with higher body weights, more with severe CSU (UAS7 ≥ 28), and a higher percentage with angioedema (82%) than the lower-dose groups and the placebo group.
- Regimens: the phase 2 groups received 150 mg every 4 weeks or 300 mg every 8 weeks for 52 weeks, with placebo injections at the intervening visits of the every-8-weeks group; the phase 3 regimens follow a 300 mg or 450 mg loading dose.
- Counts that differ across documents: the study is described as conducted across 9 countries (Form 10-Q), at ~75 sites in 10 countries (52-week presentation), and at 56 locations (registry); the 300 mg every 8 weeks group is n = 51 in the primary publication and n=52 in the 52-week presentation.
- Immunogenicity: no antidrug antibody results from this study were found.
- Pigmentation analysis: the authors state “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes” and that images were obtained from a subset of participants.

Source: [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018); [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm); [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf); [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf); [Metz et al. (2025c)](https://celldex.com/wp-content/uploads/2025/06/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf); [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf); [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf); [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf); [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
